Confirmed Speakers

Varinder Aggarwal was born in India in 1961. He studied chemistry at Cambridge University and received his Ph.D. in 1986 under the guidance of Dr. Stuart Warren. After postdoctoral studies (1986-1988) under Prof. Gilbert Stork, Columbia University, he returned to the UK as a Lecturer at Bath University. In 1991 he moved to Sheffield University, where he was promoted to Professor in in 1997. In 2000 he moved to Bristol University where he holds the Chair in Synthetic Chemistry. He has received numerous awards including RSC Hickinbottom Fellowship (1997); RSC Corday Morgan Prize (1999); Novartis Lecturship (1999/2000); Liebigs Lecturship (Germany), (1999/2000) (inaugural); RSC Green Chemistry Award (2003); RSC Reaction Mechanism Award (2004); RSC/GDCh-Alexander Todd-Hans Krebs Lectureship (2007) (inaugural); RSC Tilden Lecturer (2007), RSC Stereochemistry Award (2009); GSK, AZ & Pfizer prize for Process Research (2009); Elected Fellow of the Royal Society (2012); RSC Perkin Award (2013). His current research interests center on the development of new catalytic processes for asymmetric synthesis.

Close window

Engaged in drug discovery, chemical synthesis of active pharmaceutical ingredients, formulation development of injectables, oral, ocular and topical products. Drug delivery systems, nanotechnologies, liposomes, emulsions, suspensions,implantable biodegradable polymers for slow release of biopharmaceuticals, encapsulation of antigens and peptides and pharmaceutical development of vaccines and adjuvants, Education and former professional experience Ph.D. in Pharmacology from the School of Pharmacy, Master in Pharmaceutical Sciences, School of Pharmacy, B. Sc. in Chemistry, all degrees from the Hebrew University of Jerusalem. Post-doctoral Fellow at the Walter Reed Army Institute of Research, Washington DC. Worked in several international pharmaceutical industries: Nova Pharmaceutical Corp. (US), Alergia Immunologia Abello SA, (Spain), Pharmos Corp. (Israel). CSO at Marval Pharma, CEO & Founder of Nextar ChemPharma Solutions.

Close window

Prof. Valentine P. Ananikov Laboratory Head of Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences and Professor of Moscow State University PhD (1999), Habilitation (2003), Laboratory Head (2004), Elected Member of the Russian Academy of Sciences (2008). Research field - Adaptive transition metal catalysis for organic synthesis. Web-site: http://AnanikovLab.ru

Close window

Steve Andrews is a Principal Scientist in the Medicinal Chemistry group at Heptares Therapeutics. Since 2008, he has applied Heptares’ structure-based design platform to drug discovery with ‘intractable’ GPCRs and has developed hits and leads for various peptide, orphan, purine and chemokine receptors. Steve co-invented Heptares’ first clinical candidate, an adenosine A2A receptor antagonist for the treatment of CNS disorders, which became the first published example of structure-based design with GPCR X-ray structures. Steve obtained his PhD from Cambridge University, where he completed the first total synthesis of thapsigargin with Professor Steve Ley CBE FRS, and undertook his post-doctoral studies at ETH-Zürich with Professor Erick Carreira.

Close window

Education:
University of Tübingen (Dipl. Biology, Dipl. Chemistry, Ph. D. Organic Chemistry with G. Jung)
ETH Zürich, Univ. Copenhagen (Post Doctorial Studies)
ETH Zürich (Assistant Professorship)
Vanderbilt University (Guest professorship)

Research Fields:
• structure-activity- relationships of peptide hormones and G protein coupled receptors
• protein modification to study function and interaction
A tight connection of chemical methods, bioorganic synthesis and molecular biology tools, including cloning, receptor mutagenesis, protein expression and cell biochemistry is applied. Whereas in the first field, the application goes towards medicinal chemistry, identification of novel targets and novel therapeutic concepts, the second field is related to biomaterials, novel approaches to modify proteins and concepts for improved enzyme catalysis.

Close window

Research Interests: 1) Chemical and semisynthesis of posttranslationally modified proteins. 2) Studying the ubiquitin and ubiquitin like modifier signals. 3) Developing assays, activity based probes and novel inhibitors for deubiquitinases. Education: 1996: B.Sc. Ben-Gurion University of the Negev; 1998: M.Sc. Technion-Israel Institute of Technology; 2001: Ph.D. Technion-Israel Institute of Technology. Professional Career: Since 2/2015 Full Professor, Schulich Faculty of Chemistry, Technion 3/2012-2/2015 Full Professor, Department of Chemistry, Ben-Gurion University. 4/2011-2/2012 Associate Professor, Department of Chemistry, Ben-Gurion University. 2/2007-3/2011 Sr. Lecturer, Department of Chemistry, Ben-Gurion University. Scientific Activities: 2009-2014 Elected member of the executive board of the Israel Chemical Society. 2012-present Member of the Editorial Board of Organic and Biomolecular Chemistry. 2012-present Member of the International Advisory Board of Asian Journal of Organic Chemistry. Honors: Bessel Award of the Humboldt Foundation for 2015, The 11th Hirata Award, Teva Award for Excellence in memory of Eli Hurvitz for 2013, The Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry for 2013, The 2011 Israel Chemical Society prize for Outstanding Young Chemist.

Close window

Dr. Alessio Ciulli is currently an Associate Professor in Chemical & Structural Biology at the University of Dundee. After graduating Magna Cum Laude in Chemistry in 2002 from his hometown Florence under guidance of the late Professor Ivano Bertini, Alessio was awarded a Gates Scholarship to study at the University of Cambridge. His PhD (2006, Chemical Biology) focused on biophysical and structural studies of protein-ligand interactions under the supervision of Professor Chris Abell at the Department of Chemistry and Dr Glyn Williams at fragment-based drug discovery company Astex Pharmaceuticals. Following post-doctoral research with Professor Abell and Professor Sir Tom Blundell, he obtained a Human Frontier Science Program visiting Fellowship at Yale University to start collaboration with Professor Craig Crews, and then returned to Cambridge to start his independent research career upon the award of a BBSRC David Phillips Fellowship (2010). In 2013 Alessio was awarded an ERC Starting Grant and moved his laboratory to the School of Life Sciences at the University of Dundee as Principal Investigator within the Division of Biological Chemistry and Drug Discovery. He is the recipient of the MIUR Award ‘Messaggeri della Conoscenza’ with the University of Messina, Italy (2013), the ‘Talented Young Italians Award’ for Research and Innovation (2014), the European Federation for Medicinal Chemistry (EFMC) Prize for a Young Medicinal Chemist in Academia (2015) and the International Chemical Biology Society (ICBS) Young Chemical Biologist Award (2015).

Close window

Ben L. Feringa obtained his PhD degree at the University of Groningen in the Netherlands under the guidance of Professor Hans Wynberg. After working as a research scientist at Shell in the Netherlands and the UK, he was appointed lecturer and in 1988 full professor at the University of Groningen and named the Jacobus H. van't Hoff Distinguished Professor of Molecular Sciences in 2004. He was elected Foreign Honory member of the American Academy of Arts and Sciences and member and vice-president of the Royal Netherlands Academy of Sciences. In 2008 he was appointed Academy Professor and was knighted by Her Majesty the Queen of the Netherlands. Feringa’s research has been recognized with a number of awards including the Koerber European Science Award (2003), the Spinoza Award (2004), the Prelog gold medal (2005), the Norrish Award of the ACS (2007), the Paracelsus medal (2008), the Chirality medal (2009),the RSC Organic Stereochemistry Award (2011), Humboldt award (2012), the Nagoya gold medal (2013) and an ACS Cope Scholar Award 2015. Feringa is currently director of the Center for Systems Chemistry at the University of Groningen. The research interest includes stereochemistry, organic synthesis, asymmetric catalysis, molecular switches and motors, self-assembly, molecular nanosystems and photopharmacology.

Close window

Department of Applied Chemistry, The University of Tokyo
1-7-3 Hongo, Bunkyo-ku, Tokyo 113-8656
Tel: +81-3-5841-7259
E-mail: mfujita@appchem.t.u-tokyo.ac.jp

Education
1980 BSc Chiba University
1982 MSc Chiba University
1987 PhD Tokyo Institute of Technology

Academic Careers
1982-1988. Researcher, Sagami Chemical Research Center.
1988 -1997 Assist. Prof. to Assoc. Prof., Chiba University.
1997- 1999 Assoc. Prof., Inst. for Molecular Science (IMS)
1999 – 2002 Professor, Nagoya University.
2004- Professor, The University of Tokyo


Close window

Fabrizio Giordanetto graduated with first class honors in Medicinal Chemistry in 2000 from University of Genoa, Italy. He completed his Ph.D. in Computational Medicinal Chemistry in 2003 at University of London, UK while working for the chemistry unit of Pharmacia (Pfizer) in Nerviano, Italy. In 2004 he joined the Medicinal Chemistry Department of AstraZeneca in Mölndal (Sweden) where he grew professionally to the position of Principal Scientist in Medicinal Chemistry and Preclinical Project Leader. Since 2013, he is Head of Medicinal Chemistry for Taros Gmbh, a research-based SME in Dortmund, Germany, where he leads medicinal chemistry activities and discovery projects.

Close window

Chief Scientific Officer and Founder of Semorex Inc. My academic research (Hebrew University, Jerusalem; Weizmann Institute, Rehovot; Sabbaticals at NIH, Bethesda, MD, USA; WRAIR, Washington, DC, USA; CNRS, Gif-sur-Yvette, France) focused on selective molecular recognition (which provided the name Semorex) involved chemical reactions in organic crystals, host-guest chemistry, extensive catalytic antibody studies and molecularly imprinted polymers. Semorex has recently developed new approaches for preparing protein imprinted polymers, an endeavor whose potential rewards are extraordinarily high but matched by equally high challenges. I have authored 100 research publications, edited two books and hold six patents.

Close window

Research field – Teva API generic R&D, Focus on development of synthetic approaches for the preparation of small molecules on the field of active pharmaceutical ingredients. Education and former professional experience - B.Sc. in Chemistry. Tel Aviv university, Israel 1995 - Master in Organic Chemistry: Bar Ilan university, Israel 1997 - Ph.D in Medicinal Chemistry, Bar Ilan university, Israel 2003

Close window

Amir H. Hoveyda is the Patricia and Joseph T. ’49 Vanderslice Millennium Professor of Chemistry at Boston College. He received his undergraduate education at Columbia, was a graduate student at Yale and a postdoctoral fellow at Harvard. Hoveyda's research interests include the discovery of new catalysts and development of efficient, sustainable and stereoselective transformations, in-depth mechanistic study of such reactions, diastereo- and enantioselective catalysis, and synthesis of complex natural products. He has published more than 200 research articles. Hoveyda's honors include an NIH MERIT Award (2005), Harvard University’s 2007 Max Tishler Prize, the 2010 Yamada-Koga Prize, the 2014 American Chemical Society Award for Creative Work in Organic Synthesis and a 2014 Eni Prize. Hoveyda is a co-founder of XiMo AG, a Swiss company that utilizes catalysts developed in his laboratories.

Close window

Dr. Philippe Nakache, serves actually as VP Chemistry at Metabomed LTD, a company focused on target and drug discovery in the field of cancer metabolism. Prior, Dr. Nakache served 8 years as the Head of Chemistry of Proteologics LTD, a company involved in ubiquitin system drug discovery. Dr. Nakache completed his B.Sc at the Universite de la Mediterranee (Marseille, France), his master from joined program of Universite de la Mediterranee and Uppsala University (Sweden). Dr. Nakache obtained his Ph.D under the guidance of Prof. Alfred Hassner at Bar-Ilan University in 2001 (Israel). In addition, He performed a Post-doctoral studies under the direction of Prof. Stephen Hanessian, Universite de Montreal. In addition, He performed a Post-doctoral studies under the direction of Prof. Stephen Hanessian, Universite de Montreal.

Close window

Alan D. Palkowitz received his B.S. degree in Chemistry from the University of California at Berkeley in 1985 where he graduated Valedictorian of the College of Chemistry. He then moved to the Massachusetts Institute of Technology where he obtained his Ph.D. in Synthetic Organic Chemistry in 1989 with Prof. William R. Roush. Later that year, Dr. Palkowitz joined Lilly Research Laboratories as a Senior Organic Chemist in Cardiovascular Research where he focused on efforts targeting hypertension and atherosclerosis. Following a promotion to Research Scientist in 1992, he joined Endocrine Research and contributed to projects directed at osteoporosis and metabolic diseases. With a re-structuring of Discovery Chemistry in 1996, Dr. Palkowitz joined the scientific management team and was promoted to Head, Discovery Chemistry Research. In 1999 he became Director with a primary focus on developing and managing the lead generation infrastructure and strategy for the organization as well as oversight of the early stage drug discovery portfolio. In 2003, Dr. Palkowitz became Executive Director, Discovery Chemistry Research and Technologies. In this capacity, he had responsibility for discovery lead generation, medicinal chemistry, computational and structural, sciences, compound library sciences, quantitative biology and analytical technologies.
In 2006, Dr. Palkowitz was promoted to Vice President, Discovery Chemistry Research &Technologies. He currently has responsibility for Lilly Global Discovery Chemistry which includes research sites in Indianapolis, San Diego, Spain and the United Kingdom, as well as several strategic partnerships. His organization is accountable for the discovery of small molecule drug candidates targeting Oncology, the CNS, Cardiovascular and Metabolic Diseases.
Dr. Palkowitz has played a key leadership role in shaping the discovery strategy, talent base and technology infrastructure at Lilly to successfully discovery high quality drug candidates against diverse therapeutic opportunities. In addition, Dr. Palkowitz has championed and implemented unique open innovation business models aimed at expanding global access to talent and novel molecules in partnership with academic centers and small biotechs. Dr. Palkowitz also serves on several executive oversight committees that set strategic direction for the company
Dr. Palkowitz is the recipient of the 2013 American Chemical Society Earl B. Barnes Award for Leadership in Chemical Research Management. He is also a co-author on numerous peer reviewed publications and is an inventor on fifty-nine U.S. patents.

Close window

Jean-Marc Plancher started his scientific career studying alpha-carbamoyl radical under the supervision of Prof. Michèle Bertrand, Marseille, France. Then, in the lab of Prof. Istvan Marko, Louvain-la-Neuve, Belgium, he applied the Intramolecular Sakurai Reaction to the total synthesis of the Monic Acid C. After completing his PhD in 2000, he joined F. Hoffmann-La Roche as a labhead in the medicinal chemistry department, working both in Basel, Switzerland and Nutley, USA. Dr. Plancher’s contributions are mostly in the field of metabolic diseases and neurology as team and project leader. Additionally, he is in charge of the Compact Module global initiative since 2012. Dr. Plancher, currently Principal Scientist at F. Hoffmann-La Roche Basel is the coauthor of 25 publications and more than 30 patent applications.

Close window

Andreas Plückthun studied chemistry at the University of Heidelberg, and received his PhD at the University of California at San Diego. He was a postdoctoral fellow at the Chemistry Department of Harvard University. He became group leader at the Genzentrum and Max-Planck-Institut für Biochemie in Martinsried. He was appointed to the University of Zurich as a Full Professor of Biochemistry in 1993. He has written over 370 publications, which have been cited over 20,000 times (h-factor 84). In 2003, he was elected to the German Academy of Science (Leopoldina). He received the Young Investigator's Award of the German Industry Fund, was elected member of EMBO, and is recipient of the Karl-Heinz-Beckurts-Prize (Munich, Germany), finalist in the World Technology Awards 2001 (London, UK), recipient of the JP Morgan Chase Health Award (San Jose, USA), the Wilhelm Exner Medal (Vienna, Austria), and together with his colleagues, the Swiss Technology Award (Bern, Switzerland) and the deVigier Award. He is co-founder and Scientific Advisor of Morphosys AG (Martinsried, Germany) and of Molecular Partners AG (Zürich, Switzerland), for which he is also a board member. His research field is protein engineering. His lab combines directed evolution, biophysics and biomedical applications. His major contributions to the field include antibody engineering, the development of true Darwinian in vitro evolution technologies, the development of new binding proteins (DARPins) and the evolution of highly stable G-protein coupled receptors.

Close window

Robert Pulz earned his chemistry diploma at the Technische Universität Dresden, Germany in 1999 and received his PhD in 2002 from the Freie Universität Berlin, Germany in the group of Prof. Hans-Ulrich Reissig. He then moved to the United States to perform postoctoral studies with Prof. Robert K. Boeckman at the University of Rochester, NY. In 2004 he joined the Novartis Institues for Biomedical Research in Basel, Switzerland as medicinal chemist, where he has worked on various discovery projects in the fields of muskoloscelatal, respiratory and autoimmune diseases. Currently he is a Senior Investigator and Project Team Head in the Discovery Chemistry department.

Close window

Manfred T. Reetz is currently emeritus group leader of the Max-Planck-Institut für Kohlenforschung (MPI) and simultaneously Hans-Meerwein-Research-Professor at the University of Marburg/Germany. During the last 15 years his group has helped to shape the emerging field of directed evolution, especially in the quest to evolve stereoselective enzymes as catalysts in organic chemistry. Previously he was director at the Mülheim MPI for two decades, and before that he held a chair in Marburg. Reetz obtained a Bachelor and Master degree in the USA and a doctoral degree under the guidance of U. Schöllkopf at Göttingen University in 1969.

Close window

Dr. Schwartz has retired from Teva Pharmaceutical industries in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman/board member of a number of life science companies, including Alcobra Ltd, BiolineRx, , D Pharm Ltd., BioCancell Ltd., CureTech Ltd, and Biomas Ltd. Dr. Schwartz also serves as a consultant to Clal Biotechnology Industries Ltd. Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr. Schwartz has received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science.

Close window

Prof. Doron Shabat has joined the School of Chemistry at Tel Aviv University in the year of 2000 after obtaining a Ph.D. degree from the Technion-Israel Institute of Technology and a postdoctoral training from The Scripps Research Institute in La-Jolla, California. He was promoted to the rank of associate professor in 2005 and to a full professor in 2008. His research interests include bioorganic chemistry, prodrug therapy, signal amplification techniques and development of novel Near Infrared probes. He is the recipient of the Juludan Prize, administered by the Technion-Israel Institute of Technology the Israel and the Israel Chemical Society’s Prize for Outstanding Young Chemists for 2005. Prof. Shabat is author and coauthor of over 90 research papers, 5 book chapters several patent applications.

Close window

Berta Strulovici, Ph.D. Director, Nancy and Steven Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel Dr. Berta Strulovici received her Ph.D from The Weizmann Institute of Science in Rehovot, Israel. She then conducted postdoctoral research under the guidance of Professor Robert J. Lefkowitz at the Howard Hughes Medical Institute Duke University Medical School in Durham, NC, USA. Berta has a track record in building and leading outstanding, productive teams, while integrating innovative processes into seamless, successful enterprises in start-up and large Pharma environments. Berta served as Director R&D at Tularik, the first start- up focused on targeting transcription factors in disease. At Merck Research Laboratories (MRL) in North Wales, PA, Berta served in positions of increased responsibilities over a period of 12 years. As Vice President of Basic Research in charge of building a stateof- the-art Center of Excellence for early drug discovery for Merck Worldwide, she and her team were involved in the discovery of lead compounds that are currently in clinical trials for various diseases. In 2012, Berta undertook a new role as Director of the Nancy and Steven Grand Israel National Center for Personalized Medicine, at the Weizmann Institute of Science. The Center has been implementing novel technologies in genomics, proteomics, bioinformatics and Chemical Biology to enable and advance Personalized Medicine and life sciences in Israel.

Close window

Dan S. Tawfik is the Nella and Leo Benoziyo Professor at the Department of Biological Chemistry of the Weizmann Institute of Science in Rehovot, Israel. He entered the field of protein evolution through his interest in enzyme engineering, when he realized that unraveling the mysteries of protein evolution is a charming intellectual endeavour as well as a powerful way of facilitating protein engineering. Research in the Tawfik laboratory integrates protein science, and chemical and evolutionary biology.

Close window

Paul Wender (Yale PhD; Columbia NIH Postdoctoral Fellow) served on the faculty at Harvard University and is currently the Bergstrom Professor of Chemistry and Professor of Chemical and Systems Biology (by courtesy, Stanford Medical School). He is an advisor to the Stanford Molecular Imaging Program, the Stanford Human Chemistry Institute (Chem-H), and several biotech companies and institutes and affiliated with the Bio-X Program, the Center for Molecular Analysis and Design, the Quantitative Chemical Biology Program, the Comprehensive Cancer Center, the Cancer Nanotechnology Program, the Molecular Therapeutics Program, and the NIH Biotechnology Training Program. His research involves studies in chemistry, biology, medicine, and materials science with an emphasis on computer-based design, new reactions, the ideal synthesis, step economy, and function oriented synthesis directed at imaging, drug delivery, resistant cancer, immunotherapy, HIV/AIDS eradication, and Alzheimer’s disease.

Close window

Itamar Willner completed his Ph.D. at the Hebrew University of Jerusalem in 1978. After a postdoctoral research at U.C. Berkeley, he joined the Hebrew University of Jerusalem in 1981, where he was appointed Professor in 1986. He coauthored over 700 research papers and monographs, and he serves on many editorial boards of scientific journals. He holds over 44,000 citations, h-index 108. He is the recipient of many awards among them The Max-Planck Research Award for International Cooperation, The Israel Chemical Society Award, The Israel Prize in Chemistry, The Rothschild Prize and the EMET Price. He is a member of the Israel Academy of Sciences, The German National Academy of Sciences – Leopoldina and the European Academy of Sciences and Arts. His research interests include supramolecular chemistry, nanobiotechnology, nanomaterials for sensing, energy conversion and nanomedicine, bioelectronics and the development of “smart” stimuli-responsive materials for drug delivery.

Close window

Prof. Albeck did his PhD with Prof. Mudi Sheves in the Department of Organic Chemistry, The Weizmann Institute of Science in Israel. He then went for post-doctoral research with Prof. Abeles in Brandeis University, USA.

Prof. Albeck has been a faculty member in the Department of Chemistry at Bar Ilan University since 1990. He is the head of the Julius Spokojny Bioorganic Chemistry Laboratory and a member of the Marcus Center for Medicinal Chemistry. Prof. Albeck was the Chairman of the Department of Chemistry, and he now serves as the Vice-Rector of Bar Ilan University.

His main research interests are in the fields of enzyme mechanism and inhibition, drug design, and synthetic chemistry of peptides and peptidomimetics.

Close window

Roey did his Ph.D. studies with Prof. Doron Shabat at TAU. After his PhD, Roey worked with Prof. Craig Hawker at the Materials Research Laboratory in University of California in Santa Barbara as post-doctoral researcher. In 2012, Roey joined the faculty of the School of Chemistry and his lab develops and studies smart polymers and macromolecular hybrids.

Close window

Julie Charpentier was born in Luxembourg (Luxembourg) in 1987. She completed her Master of Science in Molecular and Biological Chemistry at the Swiss Federal Institute of Technology Lausanne (EPFL) in 2011, carrying out undergraduate research in the group of Prof. Jérôme Waser. She then moved to Stanford, California (USA) to realize her Master thesis in the group of Prof. Barry M. Trost on asymmetric allylic alkylations of ester enolate surrogates. After an industrial internship in exploratory medicinal chemistry at Novartis Pharma AG in Basel (Switzerland), she joined the group of Prof. Antonio Togni at ETH Zürich in 2012 for her PhD studies. Her current research includes the development and application of hypervalent iodine reagents for fluorination and fluoralkylation.

Close window

I was born in Calgary, Alberta, Canada and after high school I moved to the University of Alberta in Edmonton where I completed undergraduate studies in pharmacology and masters studies in chemical biology under the supervision of Dr. Chris Cairo. In 2013, after the completion of my MSc degree, my lust for travelling brought me to Prague to pursue a PhD in the group of Prof. Michal Hocek at the Institute of Organic Chemistry and Biochemistry where I am currently in my 3rd year of study.

Close window

Dr. Jim-Min Fang received his B. S. degree in 1974 from the National Taiwan University (Department of Chemistry) and Ph. D. degree in 1980 from Yale University. After finishing postdoctoral research in Columbia University and in the Suntory Institute for Bioorganic Research (Osaka), he joined the Department of Chemistry, National Taiwan University, as Associated Professor in 1982, and promoted to Professor in 1986. He served as departmental chairman from 1993 to 1996. He is now a Distinguished Professor of National Taiwan University and TBF Chair in Biotechnology. He also holds a joint appointment in the Genomics Research Center, Academia Sinica.

Professor Fang has obtained several prestige awards: National Science Council Award for Outstanding Research (1987–96) and Invited Principal Investigator (1997–2003), Sun Yat-Sen Award for Academic Publications (1992), Chinese Chemical Society Award (1997), National Taiwan University Award for Teaching Excellence (1999), Chair Professor of Foundation for Advancement of Outstanding Scholarship (1999–2004), TienTe Lee Award for Outstanding Medical and Pharmaceutical Science and Technology (2009), Ministry of Education’s Academic Award (2009), and TBF Chair in Biotechnology of Taiwan Bio-Development Foundation (2014–present).

His current research interests are organic synthesis and chemical biology, including new synthetic methods, asymmetric catalysis, biomolecular recognition, natural products and drug discovery. He is the author and co-author of over 240 publications, 20 patents, and three books. He also serves in scientific advisory board of several research institutes and pharmaceutical companies.

Close window

Lecturer, Institute of Molecular and Cellular Biosciences, The University of Tokyo (Laboratory of Bioorganic Chemistry, director: Prof. Yuichi Hashimoto)

2000 BS Faculty of Pharmaceutical Sciences, TheUniversity of Tokyo (Prof. Koichi Shudo)
2002 Master, Graduate School of Pharmaceutical Sciences, The University of Tokyo
2002-Researcher, Kyowa Hakko Kogyo Co.Ltd(a Japanese pharmaceutical company)
2004-Research Associate, Faculty of Pharmaceutical Sciences, Tokushima Bunri University
2006 -Assistant Professor,Tokyo Medical and Dental University (Laboratory directed byProf. H.Kagechika)
2009 Ph.D. The University of Tokyo (Application of boron clusters in medicinal chemistry, supervisor: Prof. Y. Hashimoto)
2013 -Lecturer, Institute of Molecular andCellular Biosciences,The University of Tokyo (Laboratory directed by Prof. Y.Hashimoto)

My main research fields:
[1]development of transcription modulators,
[2]development of element chemistry approach for medicinal chemistry and chemical biology

Close window

Prof. Goldblum is Head of the Molecular Modeling and Drug Design and Discovery Unit at the Institute for Drug Research of the Hebrew University. Following a BSc in Chemistry and Physics and a MSc in QM studies of molecular spectra, Goldblum wrote his PhD in Organic Reaction Mechanisms (Hebrew University) and continued with postdoc studies of Quantum Biochemistry (Paris), and of QSAR and QM reaction mechanisms (California).
Back at Hebrew U, Goldblum performed research of protein reactions and interactions using semiempirical QM and developed MNDO/H for dealing with H-bonding in relatively large molecular systems. Since 2000, Goldblum's group focuses on applications of his prize winning generic algorithm (ACS "emerging technologies", Washington D.C. 2000) for finding sets of best solutions in extremely complex combinatorial problems. ISE (Iterative Stochastic Elimination) has been applied to protein structure and conformations, to protein-protein and protein-ligand interactions, to molecular properties and to the discovery of drug candidates.

Close window

Pavel Mykhailiuk was born in Kerch, Ukraine in 1984. In 2000 he won a bronze medal at 32nd International Chemistry Olympiads, IChO (Copenhagen, Denmark). In 2008 he received PhD in Biochemistry at Technical University of Karlsruhe (KIT, Germany) after working with Prof. Anne Ulrich. Thereafter, he joined the Kyiv National Taras Shevchenko University (Ukraine), where he obtained PhD in Chemistry under the supervision of Prof. Igor Komarov. Since then Pavel holds a position Senior Scientist at this University. Independently, in 2009 he joined “Enamine LTD” company (Ukraine), where in 2011 he became a head of custom synthesis department; and since 2013 he holds a position of Chief Scientific Officer (CSO). Pavel´s research interests include fluorine-containing compounds, conformationally restricted molecules, 3D-shaped unnatural scaffolds and their application in medicinal chemistry. He is co-author of more than 80 research manuscripts, 1 patent and 1 book chapter. In 2014 he was selected as a runner up of EFMC Prize for a Young Medicinal Chemist in Industry.

Close window

I am a second year Master student in Chemistry Department, University of Warsaw, Poland. I am carrying out my research in Laboratory of Organometallic Synthesis, Biological an Chemical Sciences Centre, in group of prof. Karol Grela. Our research aims to organometallic chemistry, especially reaction called olefin metathesis, catalysed by transition metals complexes. My work is focused on developing a new methodology, activities and apllications of olefin metathesis.

Close window

Stephan Scheeff was born in 1988 in south Germany. In 2008 he moved to Berlin and started his studies in chemistry at the Humbold-University of Berlin. In 2014 he finished his diploma under the supervision of Prof. Dr. Rainer Mahrwald. His research topic was direct asymmetric organocatalytic aldol reactions catalyzed by amino acids. In this time he was funded and supported by the Friedrich-Ebert-Foundation. Since January 2015 he has been working in the group of Prof. Dr. Dirk Menche at the University of Bonn for his PhD studies. His research interests include the total synthesis and derivatisation of natural products.

Until now, he is working with archazolids which is an interesting natural product with an inhibitor potency against V-ATPase.

Close window

Date of birth, 5 Aug 1968
1991 Graduated from The University of Tokyo (Professor Masaji. Ohno)
1993 Obtained master degree from The University of Tokyo (Professor Masakatsu. Shibasaki)
1993 Joined to Institute of Microbial Chemistry as a researcher
2000 Obtained Ph. D. (Keio University (Professor Kazuo Umezawa))
2002-2004 Post doctoral work at ETH Zurich (Professor Erick M. Carreira)
2004 Back to Institute of Microbial Chemistry
2010 Promoted to Chief Researcher of Institute of Microbial Chemistry (Laboratory of Synthetic Organic Chemistry, Professor Masakatsu. Shibasaki)
2015- Promoted to Laboratory Head for Laboratory of Synthetic Organic Chemistry in Institute of Microbial Chemistry (Professor M. Shibasaki)

Close window